Abstract
Histone deacetylase inhibitors comprise a variety of natural and synthetic compounds, which have in common that they inhibit enzymes that mediate the removal of acetyl groups from a range of proteins, including nucleosomal histones. Histone deacetylase inhibitors have anti-cancer activities in vitro and in vivo and are used in the clinic for the treatment of advanced cutaneous T cell lymphoma. The molecular pathways targeted by these compounds are discussed with an emphasis on the effects of these compounds on retinoic acid signaling.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
DNA Methylation
-
Enzyme Inhibitors / pharmacology*
-
Epigenesis, Genetic
-
Histone Deacetylase Inhibitors*
-
Histone Deacetylases / metabolism
-
Histones / metabolism*
-
Humans
-
Lymphoma, T-Cell, Cutaneous / drug therapy
-
Models, Biological
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Neoplasms / metabolism
-
Tretinoin / metabolism
Substances
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Histone Deacetylase Inhibitors
-
Histones
-
Tretinoin
-
Histone Deacetylases